Oral Rivaroxaban for Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring. METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. In parallel, we carried out a double-blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism. The primary efficacy outcome for both studies was recurrent venous thromboembolism. The principal safety outcome was major bleeding or clinically relevant nonmajor bleeding in the initial-treatment study and major bleeding in the continued-treatment study. RESULTS: The study of rivaroxaban for acute DVT included 3449 patients: 1731 given rivaroxaban and 1718 given enoxaparin plus a vitamin K antagonist. Rivaroxaban had noninferior efficacy with respect to the primary outcome (36 events [2.1%], vs. 51 events with enoxaparin-vitamin K antagonist [3.0%]; hazard ratio, 0.68; 95% confidence interval [CI], 0.44 to 1.04; P<0.001). The principal safety outcome occurred in 8.1% of the patients in each group. In the continued-treatment study, which included 602 patients in the rivaroxaban group and 594 in the placebo group, rivaroxaban had superior efficacy (8 events [1.3%], vs. 42 with placebo [7.1%]; hazard ratio, 0.18; 95% CI, 0.09 to 0.39; P<0.001). Four patients in the rivaroxaban group had nonfatal major bleeding (0.7%), versus none in the placebo group (P=0.11). CONCLUSIONS: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation. (Funded by Bayer Schering Pharma and Ortho-McNeil; ClinicalTrials.gov numbers, NCT00440193 and NCT00439725.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
Citations
Cites
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Turpie, A. G., Lassen, M. R., Davidson, B. L., Bauer, K. A., Gent, M., Kwong, L. M., Cushner, F. D., Lotke, P. A., Berkowitz, S. D., Bandel, T. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60734-0 · Cited by 981
In-Stent Restenosis in the Drug-Eluting Stent Era
Dangas, G. D., Claessen, B. E., Caixeta, A., Sanidas, E. A., Mintz, G. S., & Mehran, R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.028 · Cited by 803
Incidence of Venous Thromboembolism: A Community-based Study in Western France
Oger, E., & the EPI-GETBO Study Group (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613887 · Cited by 711
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Rodger, M. A., Kahn, S. R., Wells, P. S., Anderson, D. A., Chagnon, I., Le Gal, G., Solymoss, S., Crowther, M., Perrier, A., White, R., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080493 · Cited by 581
Research works printed but not linked: 1
- Hutten BA, 2006, Cochrane Database Syst Rev, 1, CD001367
Cited by
Items 301–400 of 1,010
Incidence of venous thromboembolism in Korea from 2009 to 2013
Hong, J., Lee, J. H., Yhim, H., Choi, W.-I., Bang, S., Lee, H., & Oh, D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191897 · Cited by 80
Ammar, A. A., Ammar, M. A., Owusu, K. A., Brown, S. C., Kaddouh, F., Elsamadicy, A. A., Acosta, J., & Falcone, G. J. (2021) · Neurocritical Care · doi:10.1007/s12028-020-01161-5 · Cited by 79
Robertson, L., Kesteven, P., & McCaslin, J. E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010956.pub2 · Cited by 78
Monagle, P., Lensing, A. W. A., Thelen, K., Martinelli, I., Male, C., Santamaría, A., Samochatova, E. V., Kumar, R., Holzhauer, S., Saracco, P., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30161-9 · Cited by 83
The role of the laboratory in treatment with new oral anticoagulants
Baglin, T. P. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12227 · Cited by 77
Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism
Girardi, L., Wang, T.-F., Ageno, W., & Carrier, M. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.318779 · Cited by 93
Uresandi, F., Monréal, M., García-Bragado, F., Domenech, P., Lecumberri, R., Escribano, P., Zamorano, J. L., Jiménez, S., Ruiz‐Artacho, P., Lozano, F., et al. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2013.07.008 · Cited by 94
Keita, I., Aubin-Auger, I., Lalanne, C., Aubert, J.-P., Chassany, O., Duracinský, M., & Mahé, I. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s131157 · Cited by 84
Prins, M. H., Bamber, L., Cano, S., Wang, M. Y., Erkens, P. M. G., Bauersachs, R. M., & Lensing, A. W. A. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.11.008 · Cited by 80
Schein, J. R., White, C. M., Nelson, W. W., Kluger, J., Mearns, E. S., & Coleman, C. I. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0088-y · Cited by 89
Trujillo‐Santos, J., Micco, P. D., Dentali, F., Douketis, J. D., Díaz‐Peromingo, J. A., Núñez, M. J., Cañas, I., Mastroiacovo, D., de Sousa, M. S., Monréal, M., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-07-0494 · Cited by 83
Lutsey, P. L., Walker, R. F., MacLehose, R. F., Alonso, Á., Adam, T. J., & Zakai, N. A. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12222 · Cited by 79
Cohen, H., Doré, C. J., Clawson, S., Hunt, B. J., Isenberg, D., Khamashta, M. A., & Muirhead, N. (2015) · Lupus · doi:10.1177/0961203315581207 · Cited by 81
Treatment of Venous Thromboembolism With New Anticoagulant Agents
Becattini, C., & Agnelli, G. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.072 · Cited by 82
Dawwas, G. K., Leonard, C. E., Lewis, J. D., & Cuker, A. C. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0717 · Cited by 83
Polyphenol compounds belonging to flavonoids inhibit activity of coagulation factor X
Bijak, M., Ponczek, M. B., & Nowak, P. (2014) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2014.01.023 · Cited by 77
Boonyawat, K., Caron, F., Li, A., Chai‐Adisaksopha, C., Lim, W., Iorio, A., Lópes, R. D., Garcia, D. A., & Crowther, M. A. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13701 · Cited by 78
Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants
Enriquez, A. A., Lip, G. Y. H., & Baranchuk, A. M. (2015) · EP Europace · doi:10.1093/europace/euv030 · Cited by 81
Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa
Siegal, D. M., Lu, G., Leeds, J. M., Karbarz, M. J., Castillo, J., Mathur, V. S., Hutchaleelaha, A., Sinha, U., Kitt, M. M., McClure, M. W., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007112 · Cited by 75
Sex Differences in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
Blanco-Molina, Á., Enea, I., Gadelha, T., Tufano, A., Bura-Rivière, A., Micco, P. D., Bounameaux, H., González, J., Villalta, J., & Monréal, M. (2014) · Medicine · doi:10.1097/md.0000000000000114 · Cited by 74
Treatment of venous thromboembolism with rivaroxaban in relation to body weight
Vedovati, M. C., Riera‐Mestre, A., Prins, M. H., Mueller, K., Cohen, A. T., Wells, P. S., Beyer‐Westendorf, J., Prandoni, P., Bounameaux, H., Kubitza, D., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-02-0087 · Cited by 79
Venous Thromboembolism in Gynecological Malignancy
Cohen, A., Lim, C. S., & Davies, A. H. (2017) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001111 · Cited by 77
Goggs, R. A. N., Blais, M., Brainard, B. M., Chan, D. L., deLaforcade, A. M., Rozanski, E. A., & Sharp, C. R. (2019) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/vec.12801 · Cited by 86
“37 These guidelines are based on a wealth of high-quality evidence resulting from large-scale randomized controlled trials.(38-49) Although some of these guidelines may be applicable to small animals, it is clear that the underlying physiology,(50-53) the overall burden of disease and the most frequently associated di…”
BackgroundNovel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism
Steffel, J., & Braunwald, E. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr052 · Cited by 78
Lin, K., & Schneeweiss, S. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.359 · Cited by 75
Beam, D. M., Kahler, Z. P., & Kline, J. A. (2015) · Academic Emergency Medicine · doi:10.1111/acem.12711 · Cited by 75
Therapeutic angiogenesis-based strategy for peripheral artery disease
Han, J., Luo, L., Marcelina, O., Kasim, V., & Wu, S. (2022) · Theranostics · doi:10.7150/thno.74785 · Cited by 80
Middeldorp, S., Prins, M. H., Pap, A. F., Lensing, A. W. A., ten Cate‐Hoek, A. J., Villalta, S., Milan, M., Beyer‐Westendorf, J., Verhamme, P. B., Bauersachs, R. M., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-01-0041 · Cited by 72
Direct oral anticoagulants: a review on the current role and scope of reversal agents
Chaudhary, R., Sharma, T., Garg, J., Sukhi, A., Bliden, K. P., Tantry, U. S., Turagam, M. K., Lakkireddy, D., & Gurbel, P. A. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01954-2 · Cited by 77
Coons, J. C., Albert, L., Bejjani, A., & Iasella, C. J. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2369 · Cited by 76
Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines
Min, S., Kim, Y. H., Joh, J. H., Kang, J. M., Park, U. J., Kim, H.-K., Chang, J.-H., Park, S. J., Kim, J. Y., Bae, J. I., et al. (2016) · Vascular Specialist International · doi:10.5758/vsi.2016.32.3.77 · Cited by 77
Novel Oral Anticoagulants in Patients With Renal Insufficiency: A Meta-analysis of Randomized Trials
Sardar, P., Chatterjee, S., Herzog, E., Nairooz, R. S., Mukherjee, D., & Halperin, J. L. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.04.015 · Cited by 70
New oral anticoagulants in elderly patients
Barco, S., Cheung, Y. W., Eikelboom, J. W., & Coppens, M. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.011 · Cited by 70
Alotaibi, G., Almodaimegh, H., McMurtry, M. S., & Wu, C. M. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.07.017 · Cited by 71
“Thirteen trials published in eleven papers [9,10,12–14,16–19,21,22] were identified by our search strategy (Fig.”
BackgroundMethodInfluentialGosselin, R. C., Francart, S. J., Hawes, E. M., Moll, S., Dager, W. E., & Adcock, D. M. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015578451 · Cited by 71
Long-term mortality after massive, submassive, and low-risk pulmonary embolism
Gupta, R., Ammari, Z. A., Dasa, O., Ruzieh, M., Burlen, J., Shunnar, K. M., Nguyen, H. T., Xie, Y., Brewster, P. S., Chen, T., et al. (2019) · Vascular Medicine · doi:10.1177/1358863x19886374 · Cited by 73
Use of direct oral anticoagulants in antiphospholipid syndrome
Cohen, H., Efthymiou, M., & Isenberg, D. A. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14017 · Cited by 73
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations
Willmann, S., Zhang, L., Frede, M., Kubitza, D., Mueck, W., Schmidt, S., Solms, A., Yan, X., & Garmann, D. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12288 · Cited by 70
The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation
Antonucci, E., Poli, D., Tosetto, A., Pengo, V., Tripodi, A., Magrini, N., Marongiu, F., Palareti, G., & START-Register (2015) · PLoS ONE · doi:10.1371/journal.pone.0124719 · Cited by 71
Bauersachs, R. M., Lensing, A. W. A., Prins, M. H., Kubitza, D., Pap, A. F., Decousus, H., Beyer‐Westendorf, J., & Prandoni, P. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-25 · Cited by 73
New oral anticoagulants: a practical guide for physicians
Hinojar, R., Jiménez-Natcher, J. J., Fernández‐Golfín, C., & Zamorano, J. L. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv002 · Cited by 74
Raskob, G. E., Ageno, W., Cohen, A. T., Brekelmans, M. P. A., GROSSO, M. A., Segers, A. E. M., Meyer, G., Verhamme, P. B., Wells, P. S., Lin, M., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00023-5 · Cited by 68
Spyropoulos, A. C., Ashton, V., Chen, Y.-W., Wu, B., & Peterson, E. D. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.08.021 · Cited by 70
Diagnostic and Therapeutic Management of Upper Extremity Deep Vein Thrombosis
Bosch, F. T. M., Nisio, M. D., Buller, H. R., & van Es, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072069 · Cited by 75
Lefebvre, P., Coleman, C. I., Bookhart, B. K., Wang, S.-T., Mody, S. H., Tran, K. N., Zhuo, D. Y., Huynh, L., & Nutescu, E. A. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2013.858634 · Cited by 66
Caldeira, D., Barra, M., Ferreira, A., Rocha, A., Augusto, A., Pinto, F. J., Costa, J. N., & Ferreira, J. J. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13412 · Cited by 73
Hypercoagulation and complement: Connected players in tumor development and metastases
Guglietta, S., & Rescigno, M. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.10.011 · Cited by 73
Bryk, A. H., Piróg, M. M., Plens, K., & Undas, A. (2016) · Vascular Pharmacology · doi:10.1016/j.vph.2016.11.003 · Cited by 72
Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants
Pollack, C. V., & Weitz, J. I. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-03-0222 · Cited by 70
Khorana, A. A., Vadhan‐Raj, S., Kuderer, N. M., Wun, T., Liebman, H. A., Soff, G. A., Belani, C. P., O'Reilly, E. M., McBane, R. D., Eikelboom, J. W., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-03-0171 · Cited by 70
“43,44,46 A recent quality assurance initiative to guide rivaroxaban use in cancer-associated thrombosis also suggested ef fi cacy/safety pro fi le to be at least non-inferior to LMWH, with the added bene fi t of reduced patient burden.”
InfluentialCampello, E., Spiezia, L., Simion, C., Tormene, D., Camporese, G., Valle, F. D., Poretto, A., Bulato, C., Gavasso, S., Radu, C. M., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018917 · Cited by 74
Fuentes, H. E., Tafur, A. J., & Caprini, J. A. (2016) · Disease-a-Month · doi:10.1016/j.disamonth.2016.03.003 · Cited by 70
The use of direct oral anticoagulants in inherited thrombophilia
Skelley, J. W., White, C. W., & Thomason, A. R. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1428-2 · Cited by 76
New oral anticoagulant agents – general features and outcomes in subsets of patients
Schulman, S. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-09-0803 · Cited by 69
“In three placebo-controlled trials the new anticoagulants always gave a substantial reduction of risk for recurrence without a significant increase of major bleeding (16, 19, 26).”
BackgroundResultGalanis, T., Thomson, L. J., Palladino, M. A., & Merli, G. J. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0559-8 · Cited by 71
Utilization and prescribing patterns of direct oral anticoagulants
Whitworth, M., Haase, K. K., Fike, D. S., Bharadwaj, R., Young, R. B., & MacLaughlin, E. J. (2017) · International Journal of General Medicine · doi:10.2147/ijgm.s129235 · Cited by 70
Cohen, A. T., Hamilton, M., Bird, A., Mitchell, S. A., Li, S., Horblyuk, R. V., & Batson, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160064 · Cited by 74
Management of acute stroke in patients taking novel oral anticoagulants
Hankey, G. J., Norrving, B., Hacke, W., & Steiner, T. (2014) · International Journal of Stroke · doi:10.1111/ijs.12295 · Cited by 63
Direct oral anticoagulants in patients with liver cirrhosis: A systematic review
Hoolwerf, E. W., Kraaijpoel, N., Buller, H. R., & van Es, N. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.08.011 · Cited by 71
Wang, C., Wu, V. C., Kuo, C., Chu, P., Tseng, H., Wen, M., & Chang, S. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009263 · Cited by 69
“ROCKET AF (Rivaroxaban Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and EINSTEIN (Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism) trials exclu…”
BackgroundHow I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy
Schulman, S. (2017) · Blood · doi:10.1182/blood-2017-03-742304 · Cited by 62
Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera
Reikvam, H., & Tiu, R. V. (2011) · Leukemia · doi:10.1038/leu.2011.314 · Cited by 68
Larsen, T. B., Nielsen, P. B., Skjøth, F., Rasmussen, L. H., & Lip, G. Y. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114445 · Cited by 64
Elshafei, M. N., Mohamed, M. F. H., El‐Bardissy, A., Ahmed, M. B., Abdallah, I. M. H., Elewa, H. F., & Danjuma, M. I.-M. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02179-4 · Cited by 72
Nederpelt, C. J., Naar, L., Krijnen, P., le Cessie, S., Kaafarani, H. M. A., Huisman, M. V., Velmahos, G. C., & Schipper, I. B. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005059 · Cited by 62
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Castellucci, L. A., Chen, V. M. Y., Kovacs, M. J., Lazo‐Langner, A., Greenstreet, P., Kahn, S., Côté, B., Schulman, S., de Wit, K., Douketis, J., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2510703 · Cited by 68
Robertson, L., Yeoh, S. E., Stansby, G. P., & Agarwal, R. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010837.pub3 · Cited by 62
Bott‐Kitslaar, D. M., Saadiq, R. A., McBane, R. D., Loprinzi, C. L., Ashrani, A. A., Ransone, T. R., Wolfgram, A. A., Berentsen, M. M., & Wysokiński, W. E. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.12.025 · Cited by 62
“This rate was similar to the no-cancer control group and congruent with outcomes of major randomized venous thromboembolism trials with rivaroxaban.(11,12) Also, the rate of venous thromboembolism recurrence within the combined group of 595 cancer patients treated with direct oral anticoagulants in 6 major trials was…”
BackgroundResultInfluentialRezuş, E., Tamba, B.-I., Bădescu, M. C., Popescu, D., Bratoiu, I., & Rezuș, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136801 · Cited by 67
New anticoagulants: how to deal with treatment failure and bleeding complications
Kazmi, R. S., & Lwaleed, B. A. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04060.x · Cited by 62
Diagnosis and management of iliofemoral deep vein thrombosis: clinical practice guideline
Liu, D. M., Peterson, E. A., Dooner, J., Baerlocher, M. O., Zypchen, L. N., Gagnon, J., Delorme, M., Sing, C. K., Wong, J., Guzman, R., et al. (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.141614 · Cited by 68
Becattini, C., Vedovati, M. C., & Agnelli, G. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2011.12.014 · Cited by 69
“The program includes two studies having enoxaparin followed by a vitamin K antagonists as comparator (one in the acute treatment of DVT and one in the acute treatment of PE), and one study having placebo as comparator, in the extended treatment of VTE [32].”
MethodBeyer‐Westendorf, J., Michalski, F., Tittl, L., Hauswald-Dörschel, S., & Marten, S. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30111-9 · Cited by 61
Spronk, H. M. H., Padró, T., Siland, J. E., Prochaska, J. H., Winters, J., van der Wal, A. C., Posthuma, J. J., Lowe, G. D. O., D’Alessandro, E., Wenzel, P., et al. (2018) · Thrombosis and Haemostasis · doi:10.1160/th17-07-0492 · Cited by 75
Gu, Z., Zhou, L., Shen, L., Zhang, C., Pu, J., Lin, H., & Liu, X.-Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00348 · Cited by 64
New oral anticoagulants: discussion on monitoring and adherence should start now!
Cate, H. T. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-8 · Cited by 62
“Subsequent large scale clinical trials established the efficacy and safety of fixed doses of dabigatran, rivaroxaban and apixaban, for preventing ischemic stroke [12-14] and (recurrent) venous thromboembolism [15-18] as compared to INR titrated warfarin.”
BackgroundRossel, A., Robert‐Ebadi, H., Combescure, C., Grosgurin, O., Stirnemann, J., Addeo, A., Garin, N., Agoritsas, T., Reny, J., & Marti, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213940 · Cited by 66
Oral Anticoagulation in the Elderly and Frail
Bauersachs, R. M., & Herold, J. (2020) · Hämostaseologie · doi:10.1055/s-0040-1701476 · Cited by 67
Clinical Guidelines for Drug-Related Peptic Ulcer, 2020 Revised Edition
Joo, M. K., Park, C. H., Kim, J. S., Park, J. M., Ahn, J. Y., Lee, B. E., Lee, J. H., Yang, H., Cho, Y. K., Bang, C. S., et al. (2020) · Gut and Liver · doi:10.5009/gnl20246 · Cited by 86
Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis
Plessier, A., Goria, O., Cervoni, J. P., Ollivier‐Hourmand, I., Bureau, C., Poujol‐Robert, A., Minello, A., Houssel‐Debry, P., Rautou, P., Payancé, A., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200104 · Cited by 69
Arachchillage, D. J., Mackie, I. J., Efthymiou, M., Isenberg, D. A., Machin, S. J., & Cohen, H. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12917 · Cited by 61
Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms
Ianotto, J., Couturier, M., Galinat, H., Mottier, D., Berthou, C., Guillerm, G., Lippert, É., & Delluc, A. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2282-5 · Cited by 60
Hill, K. M., Sucha, E., Rhodes, E., Carrier, M., Garg, A. X., Harel, Z., Hundemer, G. L., Clark, E. G., Knoll, G. A., McArthur, E., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.1835 · Cited by 60
Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis
Enden, T., Resch, S., White, C., Wik, H. S., Kløw, N. E., & Sandset, P. M. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12184 · Cited by 62
Siè, P., Samama, C. M., Godiér, A., Rosencher, N., Steib, A., Llau, J. V., der Linden, P. V., Pernod, G., Lecompte, T., Gouin‐Thibault, I., et al. (2011) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/j.annfar.2011.06.018 · Cited by 59
Goto, S., Haas, S. K., Ageno, W., Goldhaber, S. Z., Turpie, A. G. G., Weitz, J. I., Angchaisuksiri, P., Nielsen, J. D., Kayani, G., Farjat, A. E., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.22886 · Cited by 61
Statins Effects on Blood Clotting: A Review
Siniscalchi, C., Basaglia, M., Riva, M. A., Meschi, M., Meschi, T., Castaldo, G., & Micco, P. D. (2023) · Cells · doi:10.3390/cells12232719 · Cited by 62
“When anticoagulation is stopped in patients with unprovoked VTE, the risk of VTE recurrence is up to 10% per year [5] whereas the recurrence rate of VTE during anticoagulation is 3% in the first 3 to 6 months [4,6].”
BackgroundBeyer‐Westendorf, J., & Buller, H. R. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04507.x · Cited by 59
Ageno, W., Rutjes, A. W., Pap, A. F., Buller, H. R., & Nisio, M. D. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-06-0474 · Cited by 62
Use of anticoagulants in elderly patients
Bauersachs, R. M. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.09.013 · Cited by 67
Moore, K. T., Plotnikov, A. N., Thyssen, A., Vaccaro, N. M., Ariyawansa, J., & Burton, P. B. J. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31822f6c2b · Cited by 59
Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM™
Casutt, M., Konrad, C. J., & Schuepfer, G. (2012) · Der Anaesthesist · doi:10.1007/s00101-012-2091-4 · Cited by 62
Skaistis, J., & Tagami, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137444 · Cited by 64
Mani, H., Kasper, A., & Lindhoff‐Last, E. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0907-y · Cited by 59
Limone, B. L., Hernández, A. V., Michalak, D., Bookhart, B., & Coleman, C. I. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.08.003 · Cited by 63
“Of 14 identified publications [12–25] one [17] reported results of two unique RCTs; thus 15 unique RCTs reporting a total of 31 treatment arms (n = 27,237 patients) were available for meta-analysis at each time point.”
BackgroundVenous thromboembolism in the elderly: A narrative review
Tritschler, T., & Aujesky, D. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.05.015 · Cited by 67
Emergency Department Discharge of Pulmonary Embolus Patients
Frank Peacock, W., Coleman, C. I., Diercks, D. B., Francis, S., Kabrhel, C., Keay, C., Kline, J. A., Manteuffel, J., Wildgoose, P., Xiang, J., et al. (2018) · Academic Emergency Medicine · doi:10.1111/acem.13451 · Cited by 57
Gómez-Outes, A., Lecumberri, R., Suárez-Gea, M. L., Terleira-Fernández, A.-I., Monreal, M., & Vargas-Castrillón, E. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415575154 · Cited by 57
“10 Case fatality VTE rate (95%CI), % 16 (7-28) 4 (0.”
Safety of direct oral anticoagulants in patients with advanced liver disease
Semmler, G., Pomej, K., Bauer, D. J. M., Balcar, L., Simbrunner, B., Binter, T., Hartl, L., Becker, J., Pinter, M., Quehenberger, P., et al. (2021) · Liver International · doi:10.1111/liv.14992 · Cited by 57
Yaghi, S. R., Saldanha, I. J., Misquith, C., Zaidat, B., Shah, A., Joudi, K., Persaud, B., Khalek, F. A., Shu, L., de Havenon, A., et al. (2022) · Stroke · doi:10.1161/strokeaha.122.039579 · Cited by 58
Metadata
- Authors
- The EINSTEIN Investigators
- Corresponding author
- The EINSTEIN Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-23
- Volume
- 363
- Issue
- 26
- Pages
- 2499-2510
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115787552
- Cited by
- 3,237
- References
- 19
- Citations by year
- 2026: 90 · 2025: 105 · 2024: 118 · 2023: 153 · 2022: 169 · 2021: 189 · 2020: 261 · 2019: 242 · 2018: 248 · 2017: 232 · 2016: 300 · 2015: 267 · 2014: 290 · 2013: 255 · 2012: 188
- FWCI
- 148.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion)
- ORBi (University of Liège) (acceptedVersion, other-oa)
- Murdoch University Research Portal (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, oral factor Xa inhibitors, venous thromboembolism, deep vein thrombosis, continuation treatment, recurrent venous thromboembolism, enoxaparin, vitamin K antagonists, warfarin, acenocoumarol, major bleeding, non-inferiority
- MeSH terms
- Rivaroxaban, Acenocoumarol, Acute Disease, Administration, Oral, Aged, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Vitamin K, Warfarin, Enoxaparin, Venous Thrombosis, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.